JP2020521794A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020521794A5 JP2020521794A5 JP2019566178A JP2019566178A JP2020521794A5 JP 2020521794 A5 JP2020521794 A5 JP 2020521794A5 JP 2019566178 A JP2019566178 A JP 2019566178A JP 2019566178 A JP2019566178 A JP 2019566178A JP 2020521794 A5 JP2020521794 A5 JP 2020521794A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- use according
- eldaphytinib
- fgfr2
- fgfr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 claims description 18
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 claims description 18
- 108091008794 FGF receptors Proteins 0.000 claims description 13
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 claims description 13
- 229940125829 fibroblast growth factor receptor inhibitor Drugs 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 8
- 206010004593 Bile duct cancer Diseases 0.000 claims description 6
- 208000026900 bile duct neoplasm Diseases 0.000 claims description 6
- 239000012472 biological sample Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000523 sample Substances 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims 7
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 7
- 239000010452 phosphate Substances 0.000 claims 7
- 210000002966 serum Anatomy 0.000 claims 7
- 230000002411 adverse Effects 0.000 claims 1
- 238000011156 evaluation Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023077882A JP2023113650A (ja) | 2017-06-02 | 2023-05-10 | 胆管癌の治療のためのｆｇｆｒ２阻害剤 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17174295 | 2017-06-02 | ||
| EP17174295.0 | 2017-06-02 | ||
| EP18171315.7 | 2018-05-08 | ||
| EP18171315 | 2018-05-08 | ||
| PCT/EP2018/064523 WO2018220206A1 (en) | 2017-06-02 | 2018-06-01 | Fgfr2 inhibitors for the treatment of cholangiocarcinoma |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023077882A Division JP2023113650A (ja) | 2017-06-02 | 2023-05-10 | 胆管癌の治療のためのｆｇｆｒ２阻害剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020521794A JP2020521794A (ja) | 2020-07-27 |
| JP2020521794A5 true JP2020521794A5 (enExample) | 2021-07-26 |
Family
ID=62555054
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019566178A Withdrawn JP2020521794A (ja) | 2017-06-02 | 2018-06-01 | 胆管癌の治療のためのｆｇｆｒ２阻害剤 |
| JP2023077882A Pending JP2023113650A (ja) | 2017-06-02 | 2023-05-10 | 胆管癌の治療のためのｆｇｆｒ２阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023077882A Pending JP2023113650A (ja) | 2017-06-02 | 2023-05-10 | 胆管癌の治療のためのｆｇｆｒ２阻害剤 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11707463B2 (enExample) |
| EP (1) | EP3634414A1 (enExample) |
| JP (2) | JP2020521794A (enExample) |
| KR (1) | KR20200010505A (enExample) |
| CN (1) | CN111050769A (enExample) |
| AU (1) | AU2018278271B2 (enExample) |
| BR (1) | BR112019025056A2 (enExample) |
| CA (1) | CA3064317A1 (enExample) |
| IL (1) | IL271058A (enExample) |
| JO (1) | JOP20190280A1 (enExample) |
| MA (1) | MA49248A (enExample) |
| MX (1) | MX2019014366A (enExample) |
| MY (1) | MY204203A (enExample) |
| PH (1) | PH12019502710A1 (enExample) |
| UA (1) | UA126478C2 (enExample) |
| WO (1) | WO2018220206A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX370099B (es) | 2014-03-26 | 2019-12-02 | Astex Therapeutics Ltd | Combinación que comprende un inhibidor de fgfr y un inhibidor de cmet para el tratamiento del cáncer. |
| JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
| JOP20190280A1 (ar) * | 2017-06-02 | 2019-12-02 | Janssen Pharmaceutica Nv | مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية |
| WO2020165181A1 (en) * | 2019-02-12 | 2020-08-20 | Janssen Pharmaceutica Nv | Cancer treatment |
| US20220054484A1 (en) * | 2019-03-29 | 2022-02-24 | Janssen Pharmaceutica Nv | Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma |
| JP2022534742A (ja) * | 2019-05-28 | 2022-08-03 | キューイーディー セラピューティクス，インコーポレイテッド | 胆管癌を治療するための方法 |
| WO2021023178A1 (zh) * | 2019-08-05 | 2021-02-11 | 江苏恒瑞医药股份有限公司 | 一种吡咯并六元杂环化合物在制备治疗fgfr2基因变异的肿瘤的药物中的用途 |
| CN114945367A (zh) * | 2020-01-17 | 2022-08-26 | 贝达医药公司 | 作为fgfr激酶抑制剂的哒嗪和1,2,4-三嗪衍生物 |
| CN111596058A (zh) * | 2020-05-18 | 2020-08-28 | 山东第一医科大学(山东省医学科学院) | 一种检测胆管癌患者外周血循环肿瘤细胞fgfr基因突变的试剂盒及检测方法 |
| DE102021126650A1 (de) | 2021-10-14 | 2023-04-20 | Rheinische Friedrich-Wilhelms-Universität Bonn, Körperschaft des öffentlichen Rechts | Verfahren zur bestimmung der ansprechwahrscheinlichkeit einer malignen erkrankung auf eine behandlung mit einem pharmazeutischen hemmwirkstoff |
| KR20250117064A (ko) | 2024-01-26 | 2025-08-04 | 충북대학교 산학협력단 | 아무렌신 g를 유효성분으로 포함하는 담관암 예방 또는 치료용 약학적 조성물 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US6218529B1 (en) | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
| WO1998004689A1 (en) | 1995-07-31 | 1998-02-05 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
| GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| EP1904480A2 (en) | 2005-05-23 | 2008-04-02 | Novartis Pharma AG | Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts |
| US8163923B2 (en) | 2007-03-14 | 2012-04-24 | Advenchen Laboratories, Llc | Spiro substituted compounds as angiogenesis inhibitors |
| JP2010525301A (ja) * | 2007-03-23 | 2010-07-22 | ザ・トランスレーショナル・ジェノミクス・リサーチ・インスティチュート | 子宮内膜癌および前癌の診断、分類および治療の方法 |
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| AR088941A1 (es) | 2011-11-23 | 2014-07-16 | Bayer Ip Gmbh | Anticuerpos anti-fgfr2 y sus usos |
| US9254288B2 (en) * | 2012-05-07 | 2016-02-09 | The Translational Genomics Research Institute | Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof |
| EP3939614A1 (en) | 2013-01-18 | 2022-01-19 | Foundation Medicine, Inc. | Methods of treating cholangiocarcinoma |
| LT3198033T (lt) | 2014-09-26 | 2022-05-10 | Janssen Pharmaceutica Nv | Fgfr mutantinių genų rinkinių panaudojimas identifikuojant vėžiu sergančius pacientus, kurie reaguos į gydymą fgfr inhibitoriumi |
| AU2016341445B2 (en) | 2015-10-23 | 2020-08-27 | Array Biopharma, Inc. | 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases |
| JOP20190280A1 (ar) * | 2017-06-02 | 2019-12-02 | Janssen Pharmaceutica Nv | مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية |
-
2017
- 2017-06-16 JO JOP/2019/0280A patent/JOP20190280A1/ar unknown
-
2018
- 2018-06-01 MY MYPI2019007030A patent/MY204203A/en unknown
- 2018-06-01 MA MA049248A patent/MA49248A/fr unknown
- 2018-06-01 MX MX2019014366A patent/MX2019014366A/es unknown
- 2018-06-01 US US16/616,067 patent/US11707463B2/en active Active
- 2018-06-01 BR BR112019025056-5A patent/BR112019025056A2/pt not_active Application Discontinuation
- 2018-06-01 EP EP18729631.4A patent/EP3634414A1/en active Pending
- 2018-06-01 WO PCT/EP2018/064523 patent/WO2018220206A1/en not_active Ceased
- 2018-06-01 AU AU2018278271A patent/AU2018278271B2/en not_active Ceased
- 2018-06-01 KR KR1020197038249A patent/KR20200010505A/ko not_active Ceased
- 2018-06-01 CN CN201880050198.0A patent/CN111050769A/zh active Pending
- 2018-06-01 UA UAA201912271A patent/UA126478C2/uk unknown
- 2018-06-01 CA CA3064317A patent/CA3064317A1/en active Pending
- 2018-06-01 JP JP2019566178A patent/JP2020521794A/ja not_active Withdrawn
-
2019
- 2019-11-29 PH PH12019502710A patent/PH12019502710A1/en unknown
- 2019-12-01 IL IL271058A patent/IL271058A/en unknown
-
2023
- 2023-05-10 JP JP2023077882A patent/JP2023113650A/ja active Pending
- 2023-06-26 US US18/341,023 patent/US12350266B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020521794A5 (enExample) | ||
| Maurer et al. | Evidence for a mitochondrial oxidative phosphorylation defect in brains from patients with schizophrenia | |
| Perez‐Ruiz et al. | A two‐stage approach to the treatment of hyperuricemia in gout: the “dirty dish” hypothesis | |
| Frisch et al. | Superior water maze performance and increase in fear-related behavior in the endothelial nitric oxide synthase-deficient mouse together with monoamine changes in cerebellum and ventral striatum | |
| Shin et al. | Carotid body denervation prevents fasting hyperglycemia during chronic intermittent hypoxia | |
| Yin et al. | Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the elderly: a meta-analysis | |
| JP2023113650A5 (enExample) | ||
| Sarin et al. | Early primary prophylaxis with beta-blockers does not prevent the growth of small esophageal varices in cirrhosis: a randomized controlled trial | |
| Wang et al. | BRG1 in the nucleus accumbens regulates cocaine-seeking behavior | |
| Liao et al. | Glucocorticoid-induced enhancement of contextual fear memory consolidation in rats: Involvement of D1 receptor activity of hippocampal area CA1 | |
| Moraska et al. | Gabapentin for the management of hot flashes in prostate cancer survivors: a longitudinal continuation study–NCCTG trial N00CB | |
| Sieland et al. | Changes in miRNA expression in patients with peripheral arterial vascular disease during moderate-and vigorous-intensity physical activity | |
| Lee et al. | Impact of postoperative hepatitis B virus reactivation in hepatocellular carcinoma patients who formerly had naturally suppressed virus | |
| McCormick et al. | The effect of aging on the autophagic and heat shock response in human peripheral blood mononuclear cells | |
| Zhang et al. | Restoring the secretory function of irradiation-damaged salivary gland by administrating deferoxamine in mice | |
| Suzuki et al. | Sustained-release lidocaine sheet for pain following tooth extraction: A randomized, single-blind, dose-response, controlled, clinical study of efficacy and safety | |
| Kimura et al. | Effects of repeated electroconvulsive shocks on dopamine supersensitivity psychosis model rats | |
| Aghajanzadeh et al. | The effect of jaw exercises on anxiety and depression in patients with head and neck cancer receiving radiotherapy: Prospective 2‐year follow‐up study | |
| Tarhzaoui et al. | Rosuvastatin positively changes nerve electrophysiology in diabetic rats | |
| Manzoni et al. | A simplified diagnostic algorithm for the management of suspected pulmonary embolism: the YEARS study | |
| Sconzo et al. | Impact of smoking on occlusion rates following stereotactic radiosurgery for Spetzler Martin grade I-III brain arteriovenous malformations–A propensity score matched analysis of the MISTA consortium | |
| Parsegian et al. | Cocaine during adolescence differentially impacts psychomotor sensitization and epigenetic profiles in adult male rats with divergent affective phenotypes | |
| Mertens et al. | Dental Implants in Medically Compromised Patients Undergoing or After Receiving Anti‐Resorptive or Radiotherapy: Retrospective Clinical and Radiographic Data | |
| Hardy et al. | Cancer-Related Fatigue | |
| Yada et al. | EFFECT OF SMOKING ON CLINICAL ATTACHMENT LEVEL PROFILE-A CROSS SECTIONAL STUDY. |